Every medical device company has a short list of surgeons who drive a disproportionate share of revenue. The top ten percent of your surgeon base probably generates forty to fifty percent of your total volume. You know their names. Your reps know their preferences. Your VP of Sales reviews their numbers every quarter.
But here is a question most companies cannot answer: which of those top surgeons is quietly considering a competitor right now?
The Problem With Revenue-Based Monitoring
Most commercial teams track surgeon value by looking at order history. High-volume surgeons get the most attention. When volume drops, someone investigates. This is reactive management — by the time the revenue decline is visible, the competitive switch is already underway.
The surgeon has already attended a competitor’s training. They have already completed a proctored case with the other company’s product. They may have already signed a purchasing agreement with the facility. The rep finds out at the next scheduled visit, three weeks too late.
Revenue is a lagging indicator of surgeon loyalty. It tells you what happened. It does not tell you what is about to happen.
Early Warning Signals Exist. Most Companies Ignore Them.
Before a surgeon reduces their use of your device, there are almost always signals – several signals.
Individually, none of these signals would raise an alarm. Together, they form a pattern that points to attrition risk. The challenge is that no human being can monitor all of these signals across hundreds or thousands of surgeons simultaneously. By the time the pattern is obvious to a regional manager reviewing a spreadsheet, the window for intervention has closed.
Your best surgeons are also your competitors’ best targets. The question is whether you find out before the switch or after the revenue disappears.